Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tacrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 16/20 | 0.93 |
| ▸ | BCHE known ✓ | P06276 | 8/20 | 0.93 |
| ▸ | TSHR | P16473 | 3/20 | 0.93 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.93 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.93 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.93 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.93 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.93 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.93 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.93 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.93 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.93 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.93 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.93 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.93 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.93 |
| ▸ | APP | P05067 | 1/20 | 0.93 |
| ▸ | FABP1 | P07148 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tacrine SCHEMBL29594645 | 0.97 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL2828 | 0.97 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL7714835 | 0.97 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL29681895 | 0.97 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL8000475 | 0.95 | ACHE (0.97) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL9407893 | 0.95 | CYP1A2 (0.97) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL7638777 | 0.95 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| SCHEMBL12043403 | 0.95 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL14236722 | 0.95 | ACHE (0.97) | ACHEBCHETSHRHSD17B10ALDH1A1 | |
| Tacrine SCHEMBL3270 | 0.95 | ACHE (1.00) | ACHEBCHETSHRHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4429648-B1 | NOVEL SYNERGISTIC COMBINATIONS BASED ON FLUOROETHYLNOREMMANTINE (FENM) AND AN ACETYLCHOLINESTERASE INHIBITOR FOR USE IN THE TREATMENT OF NEURODEGEATIVE DISEASES | REST THERAPEUTICS (FR) | 2026-05-13 | — | — | EP | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250000818-A1 | NEW SYNERGISTIC COMBINATIONS BASED ON FENM AND AN ACETYLCHOLINESTERASE INHIBITOR | REST THERAPEUTICS (FR) | 2025-01-02 | — | — | US | disclosed |
| EP-4429648-A1 | NEW SYNERGISTIC COMBINATIONS BASED ON FENM AND AN ACETYLCHOLINESTERASE INHIBITOR | REST THERAPEUTICS (FR) | 2024-09-18 | — | — | EP | disclosed |
| US-20230364074-A1 | Compounds and Compositions for Disrupting Programmed Ribosomal Frameshifting | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-16 | — | — | US | disclosed |
| WO-2023079187-A1 | NEW SYNERGISTIC COMBINATIONS BASED ON FENM AND AN ACETYLCHOLINESTERASE INHIBITOR | REST THERAPEUTICS (FR) | 2023-05-11 | — | — | WO | disclosed |
| US-20220334101-A1 | MODULATING EXTRACELLULAR MATRIX MOVEMENT | HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT (GMBH) (DE) | 2022-10-20 | — | — | US | disclosed |
| US-11242555-B2 | Molecular sensors and uses thereof | NEW YORK UNIVERSITY (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200095627-A1 | MOLECULAR SENSORS AND USES THEREOF | NEW YORK UNIVERSITY | 2020-03-26 | — | — | US | disclosed |
| EP-2576778-B1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN RODENTS | UNIV KYOTO (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-9273364-B2 | Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in mammalian organisms | KYOTO UNIVERSITY (JP) | 2016-03-01 | — | — | US | disclosed |
| US-20130137099-A1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN MAMMALIAN ORGANISMS | KYOTO UNIVERSITY (JP) | 2013-05-30 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| CN-101896161-A | Solid formulations of crystalline compounds | PURDUE RESEARCH FOUNDATION | 2010-11-24 | — | — | CN | disclosed |
| US-20100222311-A1 | SOLID FORMULATIONS OF CRYSTALLINE COMPOUNDS | PURDUE RESEARCH FOUNDATION (US) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364074-A1 | Compounds and Compositions for Disrupting Programmed Ribosomal Frameshifting | SYNCRIP, FUS, SARS1 | ACHE 4159/4885BCHE 3383/4885TSHR 4801/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | ACHE 281/4885BCHE 1637/4885TSHR 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.